RDNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RadNet Inc (RDNT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has strong growth potential in the outpatient diagnostic imaging sector and favorable analyst ratings, the recent financial performance, technical indicators, and insider selling suggest caution. The stock's current technical setup and lack of strong proprietary trading signals do not support an immediate buy decision.
The technical indicators show a bearish trend. The MACD is negative and expanding, RSI is neutral, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of 59.549, with resistance at 62.311. The pre-market price of 59.23 is slightly below the S1 support level, suggesting potential weakness.
KeyBanc initiated coverage with an Overweight rating and a $92 price target, citing strong growth drivers and reasonable targets for 2025-
Hedge funds are increasing their positions, with a 139.49% increase in buying activity over the last quarter.
Insider selling by the Chief Strategy Officer, reducing his holdings by 1%, may indicate caution.
The stock has fallen 12% recently, reflecting investor skepticism despite solid fundamentals.
Weak financial performance in Q4 2025, with declining net income, EPS, and gross margin.
In Q4 2025, revenue increased by 14.80% YoY to $547.7 million, but net income dropped to -$597,000 (-111.17% YoY), and EPS fell to -$0.01 (-114.29% YoY). Gross margin also declined significantly to 4.79 (-54.47% YoY), indicating challenges in profitability.
KeyBanc initiated coverage with an Overweight rating and a $92 price target, highlighting the company's strong growth potential in the outpatient diagnostic imaging sector, supported by favorable Medicare rates, AI benefits, and capital deployment opportunities.
